Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress

被引：0

作者：

Paik, P. ^{[1
]}

Sakai, H. ^{[2
]}

Bruns, R. ^{[3
]}

Scheele, J. ^{[4
]}

Straub, J. ^{[5
]}

Felip, E. ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[2] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan

[3] Merck KGaA, Biostat, Darmstadt, Germany

[4] Merck KGaA, Clin Oncol, Darmstadt, Germany

[5] Merck KGaA, Global Early Dev, Darmstadt, Germany

[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

546TiP

引用

页数：1

共 50 条

[41] Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC
Griesingerl, Frank
Garassino, Marina
Felip, Enriqueta
Sakai, Hiroshi
Le, Xiuning
Veillon, Remi
Smit, Egbert
Raskin, Jo
Thomas, Michael
Ahn, Myung-Ju
Lee, Matthew
Vlassak, Soetkin
Bruns, Rolf
Johne, Andreas
Palle, Paul K.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E37 - E38
[42] VALIDATING THE RESULTS OF A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
Hatswell, A.
Batteson, R.
Hook, E.
Wheat, H.
Vioix, H.
McLean, T.
Alexopoulos, S.
Baijal, S.
VALUE IN HEALTH, 2022, 25 (12) : S21 - S22
[43] Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).
Kim, So Yeon
Bohlman, Stephen
Yin, Jun
Cheng, Haiying
Walker, Phillip
Dacic, Sanja
Kim, Chul
Khan, Hina
Liu, Stephen V.
Ma, Patrick C.
Nagasaka, Misako
Reckamp, Karen L.
Abraham, Jim
Uprety, Dipesh
Halmos, Balazs
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
Gasking, Stephanie
Reinmuth, Niels
Mazieres, Julien
Popat, Sanjay
Paz-Ares, Luis
Hook, Emma
Hatswell, Anthony
Vlassak, Soetkin
Johne, Andreas
Vioix, Helene
Paik, Paul
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 132 - 133
[45] Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Yang, Mo
Vioix, Helene
Hook, Emma S.
Hatswell, Anthony J.
Batteson, Rachael L.
Gaumond, Bruce R.
O'Brate, Aurora
Popat, Sanjay
Paik, Paul K.
VALUE IN HEALTH, 2023, 26 (08) : 1155 - 1163
[46] The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Salgia, Ravi
Sattler, Martin
Scheele, Juergen
Stroh, Christopher
Felip, Enriqueta
CANCER TREATMENT REVIEWS, 2020, 87
[47] Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer
Wang, Mengchao
Zhang, Shao
Yi, Dan
Ou, Yan
Xie, Shuqi
Zeng, Chuanxiu
Qin, Xueqian
Zhao, Lu
Wang, Zhen
Kong, Fanming
Chen, Liwei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (02)
[48] Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
Caixia Ding
Yanyi Qiu
Juan Zhang
Wei Wei
Hongbian Gao
Yong Yuan
Xiaomin Wang
BMC Pulmonary Medicine, 23
[49] Phase II Trial of Ensartinib for Advanced or Metastatic Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Xia, Y.
Zhou, M.
Tian, P.
Zhao, J.
Jin, Y.
Guo, Z.
Miao, D.
Lu, Y.
Le, X.
Zhang, Y.
Li, W.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S76 - S77
[50] Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
Ding, Caixia
Qiu, Yanyi
Zhang, Juan
Wei, Wei
Gao, Hongbian
Yuan, Yong
Wang, Xiaomin
BMC PULMONARY MEDICINE, 2023, 23 (01)

← 1 2 3 4 5 →